Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$263.71M+376.77%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Dean Halbert
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,846
- Beta
- 0.68
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 6.68
Financials
Revenue
$263.71M+376.8%Net Income
$-637.0K-104.7%EBITDA
$15.15M-65.2%Free Cash Flow
$28.94MEPS (diluted)
$-0.00-100.4%Shares Outstanding (diluted)
282.89M+1165.4%Operating Expenses
$152.67MCash & Debt
$793.12MReturn of Capital
$21.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $812.03M | $-537.96M | $-1.91 |
| 2024 | $412.26M | $-281.89M | $-2.70 |
| 2023 | $306.13M | $-341.42M | $-1.82 |
| 2022 | $258.49M | $-320.83M | $-1.57 |
| 2020 | $294.01M | $27.73M | $1.55 |
| 2019 | $416.54M | $31.01M | $1.72 |
| 2018 | $432.10M | $78.60M | $3.97 |
| 2017 | $348.39M | $72.06M | $3.74 |
| 2016 | $294.35M | $6.00M | $0.31 |
| 2015 | $249.67M | $26.84M | $1.29 |
| 2014 | $227.59M | $60.27M | $2.91 |
| 2013 | $212.41M | $63.93M | $2.89 |
| 2012 | $173.93M | $63.47M | $3.26 |
| 2011 | $125.71M | $50.19M | $2.60 |
Valuation
CAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (10)
- Newsinvestors.com·3d ago·Positive
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
View source ↗ - News (RSS)yahoo·13d ago·Positive
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
View source ↗ - Newsseekingalpha.com·18d ago·Positive
…owth With Room To Run Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI's Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.
View source ↗ - Newszacks.com·20d ago·Neutral
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock? Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsprnewswire.com·28d ago·Positive
… through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.
View source ↗ - News (RSS)economictimes·33d ago·Neutral
NCDEX, CAI join hands to boost India’s cotton derivatives market NCDEX and the Cotton Association of India have signed a five-year partnership to expand cotton derivatives participation, improve price discovery and strengthen risk management through greater futures adoption across India’s cotton value chain.
View source ↗ - Newsproactiveinvestors.co.uk·39d ago·Neutral
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-p…
View source ↗ - Newsprnewswire.com·40d ago·Neutral
…y, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrate…
View source ↗ - News (RSS)businessinsider·40d ago·Neutral
Associa’s Crystal Webb Named to 2026 CAI Keystone Emerging Leaders Under 40 Class <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left" style="padding-left:0px;">DALLAS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=d2sTbunw7wDzZkkKaNuYPUoVfvV9EKEsSvPJtu3WEcK2VfcIjhSUPQrQV_ibIKnhhLf7nMvPno5GM6H4m0cikg==" rel="nofollow"...
View source ↗ - Newsdefenseworld.net·50d ago·Neutral
Head to Head Comparison: Caris Life Sciences (CAI) vs. Its Competitors Caris Life Sciences (NASDAQ: CAI - Get Free Report) is one of 110 public companies in the "Life Sciences Tools and Services" industry, but how does it contrast to its rivals? We will compare Caris Life Sciences to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, dividends and institutional ownership.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.03 per share
Typical surprise +145.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.00 vs $0.01miss
- Thu, May 7$-0.00 vs $-0.02beat
- Thu, Feb 26$0.28 vs $0.01beat
- Wed, Nov 5$0.08 vs $-0.08beat
- Tue, Aug 12$-0.54 vs $-0.21miss
- Mon, Jun 9$-0.35 vs $-0.22miss
Estimates and results for CAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAI officers and directors.
- Bought
- $2.4m
- Sold
- $28.9m
6 trades
7 trades
- Denton John Russelsold
- Brille Brian Jsold
- Spetzler David Baxleysold
- Spetzler David Baxleysold
- Spetzler David Baxleysold
- Halbert Jonbought
- Vacirca Jeff Lbought
- Power Luke Thomassold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.